Skip to main content

Advertisement

Table 1 Cell death in MCL cell lines, exposed to anti-CD20 antibody and PBMC pre-treated with ibrutinib

From: Ibrutinib inhibits antibody dependent cellular cytotoxicity induced by rituximab or obinutuzumab in MCL cell lines, not overcome by addition of lenalidomide

Ibrutinib (µM) Cell death (± SD) p-value Cell death (± SD) p-value
JeKo-1 Rituximab (1 µM) Obinutuzumab (1 µM)
 0.1 0.49 ± 0.12 0.145 0.48 ± 0.00 0.003*
 0.5 0.25 ± 0.06 0.023* 0.40 ± 0.11 0.118
 1 0.20 ± 0.03 0.024* 0.17 ± 0.06 0.005*
 5 0.21 ± 0.02 0.012* 0.11 ± 0.01 0.008*
REC-1 Rituximab (1 µM) Obinutuzumab (1 µM)
 0.1 0.71 ± 0.06 0.126 0.93 ± 0.03 0.222
 0.5 0.70 ± 0.03 0.056 0.86 ± 0.01 0.044*
 1 0.54 ± 0.11 0.152 0.79 ± 0.07 0.204
 5 0.27 ± 0.00 0.001* 0.39 ± 0.05 0.056
  1. * p < 0.05, student’s t-test, compared to control